BioCentury | Dec 11, 2018
Distillery Therapeutics

Cancer

...no treatment. Next steps could include optimizing the vaccine to improve potency. Immutep Ltd. and Neopharm...
BioCentury | Aug 11, 2014
Clinical News

Pixuvri pixantrone regulatory update

...B cell non-Hodgkin’s lymphoma (NHL) in patients who have received <=3 prior courses of treatment. Neopharm...
BioCentury | May 5, 2014
Clinical News

CVac: Phase II started

...The product has Orphan Drug designation in the U.S. and EU. In February, Prima granted Neopharm...
BioCentury | Mar 3, 2014
Company News

Neopharm, Prima BioMed deal

...Prima granted Neopharm an exclusive license to market Prima's CVac in Israel and the Palestinian Authority...
...the deal. Prima will receive a "small" upfront payment and is eligible for development milestones. Neopharm...
...CD227 ) and a mannan-fusion protein (M-FP). The companies declined to disclose financial details. Neopharm...
BioCentury | Jan 20, 2014
Company News

GW Pharma, Ipsen sales and marketing update

...Europe and Mexico. Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) has exclusive rights in the U.S. Neopharm...
BioCentury | Dec 23, 2013
Company News

Warnex supply/service news

...Research S.A.S. (Rennes, France) in December 2012 and sold its Analytical Services division to its NeoPharm...
BioCentury | Dec 9, 2013
Clinical News

Sativex regulatory update

...rights in the rest of Europe and Mexico. Otsuka has exclusive rights in the U.S. Neopharm...
BioCentury | Nov 18, 2013
Company News

Neopharm, Prima BioMed deal

...Prima entered into a binding term sheet to grant Neopharm an exclusive license to market Prima's...
...term sheet. Prima will receive a "small" upfront payment and is eligible for development milestones. Neopharm...
...product has Orphan Drug designation in the U.S. and EU (see BioCentury, June 6, 2011). Neopharm...
BioCentury | Oct 28, 2013
Clinical News

Sativex regulatory update

...rights in the rest of Europe and Mexico. Otsuka has exclusive rights in the U.S. Neopharm...
BioCentury | Oct 28, 2013
Company News

Trion Pharma cancer news

...payments covering their wages and salaries up until the end of the year. In July, Neopharm...
Items per page:
1 - 10 of 290
BioCentury | Dec 11, 2018
Distillery Therapeutics

Cancer

...no treatment. Next steps could include optimizing the vaccine to improve potency. Immutep Ltd. and Neopharm...
BioCentury | Aug 11, 2014
Clinical News

Pixuvri pixantrone regulatory update

...B cell non-Hodgkin’s lymphoma (NHL) in patients who have received <=3 prior courses of treatment. Neopharm...
BioCentury | May 5, 2014
Clinical News

CVac: Phase II started

...The product has Orphan Drug designation in the U.S. and EU. In February, Prima granted Neopharm...
BioCentury | Mar 3, 2014
Company News

Neopharm, Prima BioMed deal

...Prima granted Neopharm an exclusive license to market Prima's CVac in Israel and the Palestinian Authority...
...the deal. Prima will receive a "small" upfront payment and is eligible for development milestones. Neopharm...
...CD227 ) and a mannan-fusion protein (M-FP). The companies declined to disclose financial details. Neopharm...
BioCentury | Jan 20, 2014
Company News

GW Pharma, Ipsen sales and marketing update

...Europe and Mexico. Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) has exclusive rights in the U.S. Neopharm...
BioCentury | Dec 23, 2013
Company News

Warnex supply/service news

...Research S.A.S. (Rennes, France) in December 2012 and sold its Analytical Services division to its NeoPharm...
BioCentury | Dec 9, 2013
Clinical News

Sativex regulatory update

...rights in the rest of Europe and Mexico. Otsuka has exclusive rights in the U.S. Neopharm...
BioCentury | Nov 18, 2013
Company News

Neopharm, Prima BioMed deal

...Prima entered into a binding term sheet to grant Neopharm an exclusive license to market Prima's...
...term sheet. Prima will receive a "small" upfront payment and is eligible for development milestones. Neopharm...
...product has Orphan Drug designation in the U.S. and EU (see BioCentury, June 6, 2011). Neopharm...
BioCentury | Oct 28, 2013
Clinical News

Sativex regulatory update

...rights in the rest of Europe and Mexico. Otsuka has exclusive rights in the U.S. Neopharm...
BioCentury | Oct 28, 2013
Company News

Trion Pharma cancer news

...payments covering their wages and salaries up until the end of the year. In July, Neopharm...
Items per page:
1 - 10 of 290